HK1071847A1 - Dosage forms having prolonged active ingredient release - Google Patents

Dosage forms having prolonged active ingredient release

Info

Publication number
HK1071847A1
HK1071847A1 HK05104615.2A HK05104615A HK1071847A1 HK 1071847 A1 HK1071847 A1 HK 1071847A1 HK 05104615 A HK05104615 A HK 05104615A HK 1071847 A1 HK1071847 A1 HK 1071847A1
Authority
HK
Hong Kong
Prior art keywords
active ingredient
dosage forms
oral administration
ingredient release
daily oral
Prior art date
Application number
HK05104615.2A
Other languages
English (en)
Inventor
Peter Truog
Original Assignee
Lunamed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunamed Ag filed Critical Lunamed Ag
Publication of HK1071847A1 publication Critical patent/HK1071847A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HK05104615.2A 2001-09-10 2005-06-01 Dosage forms having prolonged active ingredient release HK1071847A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01810865A EP1291015A1 (en) 2001-09-10 2001-09-10 Dosage forms having prolonged active ingredient release
PCT/CH2002/000486 WO2003022253A1 (en) 2001-09-10 2002-09-04 Dosage forms having prolonged active ingredient release

Publications (1)

Publication Number Publication Date
HK1071847A1 true HK1071847A1 (en) 2005-08-05

Family

ID=8184126

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104615.2A HK1071847A1 (en) 2001-09-10 2005-06-01 Dosage forms having prolonged active ingredient release

Country Status (13)

Country Link
US (1) US7611729B2 (ja)
EP (2) EP1291015A1 (ja)
JP (1) JP2005508901A (ja)
CN (1) CN100508965C (ja)
AT (1) ATE455539T1 (ja)
AU (1) AU2002322964B2 (ja)
CA (1) CA2459165C (ja)
DE (1) DE60235178D1 (ja)
DK (1) DK1427396T3 (ja)
ES (1) ES2339536T3 (ja)
HK (1) HK1071847A1 (ja)
PT (1) PT1427396E (ja)
WO (1) WO2003022253A1 (ja)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
EP2397458A1 (en) 2010-06-21 2011-12-21 Lunamed AG Organic salts and co-crystals of phenylbutyric acid
EP2599483A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid formulation
EP2599477A1 (en) 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
EP2599481A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment or prevention of various diseases
EP2599767A1 (en) 2011-11-30 2013-06-05 Lunamed AG Phenylbutyl-derivatives
EP2599482A1 (en) * 2011-11-30 2013-06-05 Lunamed AG Low dose therapeutic use of glyceryl tri-(4-phenylbutyrate)
EP2607366A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate esters
EP2607367A1 (en) 2011-12-21 2013-06-26 Lunamed AG Glycerol phenyl butyrate derivatives
EP2698156A1 (en) 2012-08-16 2014-02-19 Lunamed AG Phenylbutyric acid for chemoprevention
EP2698155A1 (en) * 2012-08-16 2014-02-19 Lunamed AG Pharmaceutical unit dosage form comprising 4-phenylbutyric acid
RU2635539C2 (ru) * 2016-03-10 2017-11-13 Федеральное государственное бюджетное учреждение науки Институт высокомолекулярных соединений Российской академии наук Полимерные водорастворимые производные 4-фенил-бутановой кислоты, обладающие противоопухолевой активностью
WO2017160345A1 (en) * 2016-03-15 2017-09-21 Acer Therapeutics Inc. Palatable compositions including sodium phenylbutyrate and uses thereof
CN106109429A (zh) * 2016-07-26 2016-11-16 北京百奥药业有限责任公司 一种苯丁酸钠片剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6037376A (en) 1991-10-21 2000-03-14 The United States Of America As Represented By The Department Of Health And Human Services Methods for therapy of cancer
AU2804592A (en) * 1991-10-21 1993-05-21 Dvorit Samid Compositions and methods for therapy and prevention of cancer, aids, and anemia
AU7973994A (en) 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US5569680A (en) 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5912269A (en) 1996-04-30 1999-06-15 Vertex Pharmaceuticals, Inc. Butyrate prodrugs derived from lactic acid
US5763488A (en) 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
AU749032B2 (en) * 1997-06-13 2002-06-20 Johns Hopkins University, The Therapeutic nanospheres
US5972995A (en) 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6262116B1 (en) 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
WO2000018394A1 (en) * 1998-09-28 2000-04-06 The Johns Hopkins University Adrenoleukodystrophy treatments and drug screening
AU3757600A (en) * 1999-03-19 2000-10-09 Vertex Pharmaceuticals Incorporated Oral low dose butyrate compositions
US6403646B1 (en) 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
AU4517201A (en) 1999-12-08 2001-06-18 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6656912B2 (en) 2000-01-20 2003-12-02 Washington University In St. Louis Methods to treat α1-antitrypsin deficiency
FR2810547B1 (fr) 2000-06-22 2004-01-30 Pasteur Institut Utilisation d'acides en c2-c10 pour la prevention des infections a bacteries a gram negatif
US6987131B1 (en) 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
WO2002028348A2 (en) * 2000-10-04 2002-04-11 The Children's Hospital Of Philadelphia Compositions and methods for treatment of cystic fibrosis
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
MXPA03006321A (es) 2001-01-16 2003-10-06 Genset Sa Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa.
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2002056823A2 (en) 2001-01-18 2002-07-25 Arnold Hoffman Redox therapy for tumors
EP1232746B1 (en) 2001-02-14 2006-06-14 Forte IQ B.V. Pharmaceutical composition comprising xanthan gum
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
AU2002250401A1 (en) 2001-03-27 2002-10-08 Circagen Pharmaceutical Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
EP1249246B1 (en) 2001-04-10 2005-09-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of an histone deacetylase inhibitor for the treatment of diseases associated with an hpv infection
US20040142859A1 (en) 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
WO2002090534A1 (en) 2001-05-02 2002-11-14 The Regents Of The University Of California Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
US6372938B1 (en) 2001-05-21 2002-04-16 Stanislaw R. Burzynski Synthesis of 4-phenylbutyric acid
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US6958352B2 (en) 2002-02-08 2005-10-25 Smithkline Beecham Corporation Compounds for inhibiting insulin secretion and methods related thereto
WO2003083067A2 (en) 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease

Also Published As

Publication number Publication date
DK1427396T3 (da) 2010-05-25
CA2459165A1 (en) 2003-03-20
WO2003022253A1 (en) 2003-03-20
AU2002322964B2 (en) 2008-10-16
ES2339536T3 (es) 2010-05-21
US20040180962A1 (en) 2004-09-16
JP2005508901A (ja) 2005-04-07
ATE455539T1 (de) 2010-02-15
CN100508965C (zh) 2009-07-08
DE60235178D1 (de) 2010-03-11
EP1427396B1 (en) 2010-01-20
CN1553799A (zh) 2004-12-08
EP1291015A1 (en) 2003-03-12
US7611729B2 (en) 2009-11-03
CA2459165C (en) 2011-07-19
PT1427396E (pt) 2010-04-14
EP1427396A1 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
HK1071847A1 (en) Dosage forms having prolonged active ingredient release
DK0759757T3 (da) Orale, væskeformige alendronatformuleringer
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
JP2006501240A5 (ja)
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
ZA200408649B (en) Opthamological use of roflumilast for the treatment of diseases of the eye
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
WO2006056711A3 (fr) Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
WO2003032928A3 (en) Therapeutic composition and use
CA2503810A1 (en) Therapeutic agent for fibromyalgia
JP2002526407A5 (ja)
JP2003514025A5 (ja)
JP2002540148A5 (ja)
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
RU2005131943A (ru) Лечебные и/или профилактические средства для хронических болезней кожи
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
AU3162701A (en) Pharmaceutical compositions for the topical administration in the oral cavity ofnon-steroid anti-inflammatory drugs useful for the stomatologic, mouth and oral cavity anti-inflammatory and analgesic therapies
TH57153B (th) วิธีการสำหรับการปรับปรุงเภสัชจลนพลศาสตร์ของทิพรานาเวียร์

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130904